Replimune goes pivotal in uveal melanoma
The group eyes a broader use than Immunocore’s Kimmtrak.
The group eyes a broader use than Immunocore’s Kimmtrak.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.